Studies have shown that CA can reduce the O‐GlcNAcylation of YAP by inhibiting cyclin‐dependent kinase 19 (CDK19), which means that CA may reverse the function of O‐GlcNAcylated YAP on the tumor inhibition effect of pVHL.135. Here, CDK19 is linked to neoplasm.